Author

Shaozhen Xie

Dana-Farber Cancer Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Bose S. KochupurakkaliD· 1 shared Changli Qian· 1 shared Elena V. IvanovaiD· 1 shared Erica M. HoldridgeiD· 1 shared Geoffrey Ira ShapiroiD· 1 shared Gordon James FreemaniD· 1 shared Guruprasad AnandaiD· 1 shared Hao GuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bose S. KochupurakkalORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting FGFR signaling overcomes therapeutic resistance and immune evasion in oncogenic PIK3CA-driven serous-like endometrial cancer

Xin Cheng, Y Zhang, Changli Qian, Erica M. Holdridge, Guruprasad Ananda, Tao Jiang, Jing Ni, Shaozhen Xie, Hao Gu, Renlei Ji, Elena V. Ivanova, Marisa R. Nucci, Zhe Wang, Kaifu Chen, Bose S. Kochupurakkal, , Jean J. Zhao

This study identifies FGFR signaling as a driver of resistance and immune evasion in PIK3CA-driven serous-like endometrial cancer and shows that dual FGFR/PI3K inhibition improves tumor control.

Nature Communications · May 4, 2026Peer-reviewedCancer Biology